Kesimpta's complicated developmental path has shaped Genmab's approach to partnerships

Much can be learned from Kesimpta's path from disappointing cancer treatment to promising sclerosis medication, according to Genmab's CEO Jan van de Winkel – even if this has led to some frustration along the way.

Photo: Mik Eskestad/ERH

Having already received approvals in the US and Europe, Novartis is currently rolling out the sclerosis drug ofatumumab in what looks like it will be a highly successful year on the market.

Genmab, which originally developed ofatumumab, known today as Kesimpta, now sees the culmination of the potential which the firm saw in the drug, but for a long time, it looked like the potential would not be met. Former owners Glaxosmithkline did not prioritize its sclerosis leg in the ten years it had rights to the drug, even though things started picking up later on.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs